Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

Ahmed Awais; Constantine S. Tam; Dimitrios Kontoyiannis; Alessandra Ferrajoli; Madeleine Duvic; Jorge Cortes; Michael J. Keating

doi:10.1086/529388

Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

Ahmed Awais, Constantine S. Tam, Dimitrios Kontoyiannis, Alessandra Ferrajoli, Madeleine Duvic, Jorge Cortes, Michael J. Keating

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.

Original language	English (US)
Pages (from-to)	e69-e71
Journal	Clinical Infectious Diseases
Volume	46
Issue number	7
DOIs	https://doi.org/10.1086/529388
State	Published - Apr 1 2008
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/529388

Cite this

@article{243553ecbe1f487fb8b2b9f37c9b78c9,

title = "Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia",

abstract = "The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.",

author = "Ahmed Awais and Tam, {Constantine S.} and Dimitrios Kontoyiannis and Alessandra Ferrajoli and Madeleine Duvic and Jorge Cortes and Keating, {Michael J.}",

note = "Funding Information: Potential conflicts of interest. M.J.K. has received research funding from Celgene, the maker of lenalidomide. A.F. has received research funding from and is a member of the Scientific Advisory Board of Celgene. All other authors: no conflicts.",

year = "2008",

month = apr,

day = "1",

doi = "10.1086/529388",

language = "English (US)",

volume = "46",

pages = "e69--e71",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

AU - Awais, Ahmed

AU - Tam, Constantine S.

AU - Kontoyiannis, Dimitrios

AU - Ferrajoli, Alessandra

AU - Duvic, Madeleine

AU - Cortes, Jorge

AU - Keating, Michael J.

N1 - Funding Information: Potential conflicts of interest. M.J.K. has received research funding from Celgene, the maker of lenalidomide. A.F. has received research funding from and is a member of the Scientific Advisory Board of Celgene. All other authors: no conflicts.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.

AB - The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.

UR - http://www.scopus.com/inward/record.url?scp=42549115862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549115862&partnerID=8YFLogxK

U2 - 10.1086/529388

DO - 10.1086/529388

M3 - Article

C2 - 18444808

AN - SCOPUS:42549115862

SN - 1058-4838

VL - 46

SP - e69-e71

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this